Evercore ISI analyst Elizabeth Anderson upgraded Doximity (DOCS) to Outperform from In Line with a price target of $70, up from $50. The firm believes the company’s fiscal 2026 guidance is conersvartive. Doximity’s formulary business is likely to grow at least mid-single-digits in fiscal 2026, which would allow the remaining pharma business to grow just 2% and still hit the current midpoint of the outlook, the analyst tells investors in a research note. Evercore believes Doximity has an “enviable model” with very high incremental EBITDA margins when revenue outperforms expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $62 from $55 at BofA
- Doximity’s Hold Rating: Balancing Optimism with Macroeconomic Caution
- Potential Regulatory Changes in Pharmaceutical Advertising Boost Doximity’s Prospects
- Doximity up 4% after Bloomberg report on pharma ad crackdown
- Doximity Co-Founder Steps Down to Advisory Role